Document:

Indemnification Agreement, between Registrant and Asthmatx, Inc.

 Exhibit 10.19 
 INDEMNIFICATION AGREEMENT 
 This Indemnification Agreement (this “Agreement”) is made and
entered into effective as of February 17, 2004 (the “Effective Date”) by and between Asthmatx, Inc., a California corporation (“Asthmatx”), and Broncus Technologies, Inc., a California corporation
(“Broncus”). 
 RECITALS 
 A. Broncus and Asthmatx have previously entered into a certain Corporate Formation Agreement dated as of December 26, 2003 (the “Formation Agreement”). Pursuant to the Formation Agreement,
Broncus contributed and assigned to Asthmatx cash and certain assets, agreements and obligations of Broncus relating to Broncus’ Alair Asthma Treatment System business (the “Alair Business”) in exchange for shares of
Asthmatx capital stock and other consideration described therein and Asthmatx assumed liabilities relating to the Alair Business. 
 B. On
December 30, 2003, Broncus distributed all of its shares of Asthmatx capital stock to its shareholders on a pro rata basis as a dividend (the “Spinoff”). 
 C. Broncus and Asthmatx are entering into this Agreement pursuant to the provisions of Section 2.3 of the Formation Agreement, under which Broncus
and Asthmatx agreed to enter into an agreement providing for certain indemnification obligations between themselves and setting forth provisions regarding certain insurance held or expected to be obtained by the parties. 
 AGREEMENT 
 NOW, THEREFORE, in
consideration of the premises and mutual agreements and covenants hereinafter set forth, and for other good and valuable consideration, the receipt of which is hereby acknowledged, Asthmatx and Broncus hereby agree as follows: 
 1. CERTAIN DEFINED TERMS. As used herein, the following terms shall have the following
meanings: 
 1.1 “Alair” means the Alair Asthma Treatment System which was originally
developed by Broncus and which has been contributed and assigned by Broncus to Asthmatx pursuant to the Formation Agreement. 
 1.2 “Alair Business” shall have the meaning given to that term in Recital A of this Agreement and includes, without limitation, the business of developing, testing, marketing, selling and otherwise
commercially exploiting Alair and any associated services. 
 1.3 “Alair Insurance”
means a “first payor” insurance policy that may be purchased by Asthmatx after the Spinoff Date (as defined below) which will provide liability insurance coverage to Asthmatx and/or Broncus for Pre-Spinoff Alair Claim Loss (as defined
below). 

 1.4 “Broncus Business” means the activities,
business and/or operations engaged in and/or conducted or carried out by Broncus, including the Exhale Business, but excluding the Alair Business. 
 1.5 “Broncus Insurance Policy” means an existing “occurrence-based” liability insurance policy that is owned by Broncus as of the Effective Date, that was issued to
Broncus prior to the Spinoff Date and which provides liability insurance coverage for Pre-Spinoff Alair Claims and/or other matters arising from events or harm occurring with respect to patients who were treated by Broncus during a specified time
period (an “Occurrence Period”). The parties acknowledge that Broncus owns several Broncus Insurance Policies for different Occurrence Periods, and that the coverage limits of each Broncus Insurance Policy vary in amount by
Occurrence Period. 
 1.6 “Exhale” means Broncus’ Exhale Airway Bypass System,
which is used to treat emphysema in humans and which is owned and retained by Broncus. 
 1.7 “Exhale
Business” means Broncus’ business of developing, testing, marketing, selling and otherwise commercially exploiting Exhale and any associated services. 
 1.8 “Liabilities” means, collectively, any and all liabilities, losses, claims, debts, duties,
obligations (including but not limited to contractual obligations), expenses, claims, deficiencies or guaranties of any type, whether accrued, absolute, contingent, matured, unmatured or otherwise. 
 1.9 “Loss” means, collectively, all Liabilities, loss, damages, expense, cost, fines, fees,
penalties, obligations or injuries, including without limitation those resulting from any and all claims, actions, suits, demands, assessments, investigations, judgments, awards, arbitrations or other proceedings, together with reasonable costs and
expenses including the reasonable attorneys’ fees and other legal costs and expenses relating thereto. 
 1.10
“Other Claim” means and includes, collectively, a claim, suit, action, arbitration, demand, investigation or other proceeding asserted, brought or made by a third party or parties to the extent that such third
party or parties seeks to recover damages caused or alleged to have been caused as a result of, or arising from: (i) any individual or individuals having been treated with or by Exhale at any time prior to the Spinoff Date; (ii) any use of
Exhale at any time prior to the Spinoff Date; or (iii) any activity, conduct or operations of the Broncus Business occurring at any time prior to the Spinoff Date. The term “Other Claim” shall not include any Pre-Spinoff Alair Claim.

 1.11 “Other Claim Loss” means Loss actually suffered or incurred by Broncus or
Asthmatx to the extent that such Loss is caused by, or results or arises from, an Other Claim. 
  

 2 

 1.12 “Pre-Spinoff Alair Claim” means a claim, suit,
action, arbitration, demand, investigation or other proceeding asserted, brought or made by a third party or parties to the extent that such third party or parties seeks to recover damages caused or alleged to have been caused as a result of, or
arising from, (a) any individual or individuals having been treated with or by Alair at any time prior to the Spinoff Date or (b) any use of Alair at any time prior to the Spinoff Date. The term “Pre-Spinoff Alair Claim” shall
not include any Other Claim. 
 1.13 “Pre-Spinoff Alair Claim Loss” means Loss (as
defined below) actually suffered or incurred by Broncus or Asthmatx to the extent that such Loss is caused by, or results or arises from, a Pre-Spinoff Alair Claim. 
 1.14 “Spinoff Date” means December 30, 2003. 
 2. Indemnification by Asthmatx. Except to the extent that Asthmatx is expressly entitled to be indemnified for such Loss by Broncus pursuant to the
provisions of Section 5.2 below, Asthmatx hereby agrees to indemnify Broncus and its successors and assigns, and any present or future officer, director, employee, affiliate, shareholder or agent of Broncus and/or its successors (collectively,
the “Broncus Indemnitees”) against, and hereby agrees to hold each Broncus Indemnitee harmless from, any and all Loss suffered or incurred by any Broncus Indemnitee arising out of the Alair Business or any of the Assumed
Liabilities (as that term is defined in the Formation Agreement), including, but not limited to Liabilities arising under the Assigned Contracts (as that term is defined in the Formation Agreement), whether based on events occurring before, on or
after the Spinoff Date (collectively, “Asthmatx Indemnified Loss”); provided however, that notwithstanding the foregoing, Asthmatx shall have no obligation to indemnify any Broncus Indemnitee under this
Section 2 for any Loss arising in whole or in part from criminal or fraudulent conduct on the part of such Broncus Indemnitee. By way of illustration and not limitation, Asthmatx Indemnified Loss: (a) shall include any Loss arising from
any claim, suit, action, arbitration, demand, investigation or other proceeding asserted, brought or made by a third party or parties to the extent that such third party or parties seeks to recover damages caused or alleged to have been caused as a
result of, or arising from, (i) any individual(s) having been treated with or by Alair at any time or (ii) any use of Alair at any time; and (b) shall not include any Broncus Indemnified Loss (as defined in Section 3).

 3. Indemnification by Broncus. Broncus hereby agrees to indemnify Asthmatx and its successors and assigns, and any present or
future officer, director, employee, affiliate, shareholder or agent of Asthmatx and/or its successors (collectively, the “Asthmatx Indemnitees”) against, and hereby agrees to hold each Asthmatx Indemnitee harmless from, any
and all Loss suffered or incurred by any Asthmatx Indemnitee arising out of the Broncus Business, whether based on events occurring before, on or after the Spinoff Date (collectively, “Broncus Indemnified Loss”);
provided however, that notwithstanding the foregoing, Broncus shall have no obligation to indemnify any Asthmatx Indemnitee under this Section 3 for any Loss arising in whole or in part from criminal or fraudulent conduct
on the part of such Asthmatx Indemnitee. By way of illustration and not limitation, Broncus Indemnified Loss: (a) shall include any 

  

 3 

 
Loss arising from any claim, suit, action, arbitration, demand, investigation or other proceeding asserted, brought or made by a third party or parties to
the extent that such third party or parties seeks to recover damages caused or alleged to have been caused as a result of, or arising from, (i) any individual(s) having been treated with or by Exhale at any time or (ii) any use of Exhale
at any time; and (b) shall not include any Asthmatx Indemnified Loss (as defined in Section 2). 
 4. Covenants Regarding
Insurance. The parties hereby agree as follows: 
 4.1 Asthmatx; Alair Insurance. Asthmatx shall use
diligent, good faith efforts to purchase and obtain the Alair Insurance, and to have the Alair Insurance become effective, as soon as reasonably practicable after the Effective Date of this Agreement. Asthmatx shall also use diligent, good faith
efforts to cause the Alair Insurance to: (a) have an aggregate coverage limit of Five Million Dollars ($5,000,000); (b) make both Asthmatx and Broncus named insureds of the Alair Insurance; and (c) cause the Alair Insurance to have a
coverage period of at least five (5) years from the date it is issued. Asthmatx shall consult with Broncus regarding the specific terms of such Alair Insurance. Asthmatx shall, at its sole expense, (a) pay all premiums and other charges
required to obtain the Alair Insurance and maintain it in effect at all times during the coverage period of the Alair Insurance and (b) take all other actions reasonably necessary or appropriate to maintain such Alair Insurance in effect at all
times during its coverage period. 
 4.2 Broncus. The parties acknowledge and agree that no further premiums or
other payments are required to be paid to keep the Broncus Insurance Policies in effect and that such “occurrence based” policies apply only to claims based on events occurring during specific Occurrence Periods. Broncus shall, at its sole
expense, take all actions reasonably necessary or appropriate to maintain each Broncus Insurance Policy in effect during the maximum time period during which such Broncus Insurance Policy can remain in effect in accordance with its current terms
without the payment of any additional premium, fee or other charge. 
 5. Insurance Allocations; Special Indemnification.
Notwithstanding anything to the contrary in Section 2, the parties hereby agree as follows: 
 5.1 First
Recourse to Alair Insurance. If either Broncus or Asthmatx incurs or suffers any Pre-Spinoff Alair Claim Loss, then it will first seek to obtain coverage for such Pre-Spinoff Alair Claim Loss from any available Alair Insurance to the maximum
extent that coverage for such Pre-Spinoff Alair Claim Loss is available under the Alair Insurance, before seeking or obtaining any coverage for such Pre-Spinoff Alair Claim Loss under any Broncus Insurance Policy. 
 5.2 Limited Indemnification by Broncus for Pre-Spinoff Alair Claim Loss. Subject to the provisions of this Section 5.2,
Broncus agrees to indemnify Asthmatx against, and to hold Asthmatx harmless from, that amount (and only that amount) of Pre-Spinoff Alair Claim Loss actually suffered or incurred by Asthmatx for which Asthmatx has not been reimbursed or provided
coverage under the Alair 

  

 4 

 
Insurance; provided that, notwithstanding the foregoing (i) under no circumstance shall Broncus be obligated to indemnify Asthmatx
for any amount of Pre-Spinoff Alair Claim Loss for which coverage is not actually available and actually provided under an Applicable Broncus Insurance Policy (as defined below) and (ii) in no event shall Broncus have any obligation under this
Section 5.2 to pay any amounts for which it is not provided coverage by a Broncus Insurance Policy. As used herein, the term “Applicable Broncus Insurance Policy” means, with respect to any Pre-Spinoff Alair Claim Loss,
the Broncus Insurance Policy (or Policies) for which insurance coverage is available to pay for liability of Broncus in respect of its obligation to indemnify Asthmatx for such Pre-Spinoff Alair Claim Loss pursuant to this Section 5.2. The
parties acknowledge and agree that the Broncus Insurance Policies also provide Broncus with insurance coverage for Other Claim Loss. The parties further acknowledge and agree that nothing in this Section 5.2 or elsewhere in this Agreement
imposes any restriction upon Broncus’ right and ability to at any time seek, obtain, be paid and retain any coverage, proceeds, reimbursements or other payments available to be paid to Broncus or payable on behalf of Broncus or for the benefit
of Broncus under any Broncus Insurance Policy or Policies as coverage or reimbursement for any Loss, Liabilities or other amounts (including, but not limited to, any Pre-Spinoff Alair Claim Loss or Other Claim Loss) and, except to the extent
expressly provided in Section 5.3, no rights shall accrue to Asthmatx as a result of the payment, for any reason, of proceeds of any Broncus Insurance Policy or Policies to Broncus or a claimant against Broncus, or on behalf of or for the
benefit of Broncus. 
 5.3 Insurance Allocation and Reimbursement. Asthmatx and Broncus acknowledge that the
total dollar amount of claims for insurance coverage that may be made against a Broncus Insurance Policy may exceed the Coverage Limit (as defined below) of that policy. Accordingly the parties desire to agree in this Section 5.3 to a mechanism
for allocating the available insurance coverage under each Broncus Insurance Policy between Pre-Spinoff Alair Claim Loss and Other Claim Loss and, accordingly, hereby agree as follows: 
 (a) Allocation. If the aggregate dollar amount of claims for insurance coverage made against a Broncus Insurance Policy and
payable thereunder exceed the Coverage Limit of such Broncus Insurance Policy, then: (i) the maximum dollar amount of the coverage of such Broncus Insurance Policy that is allocated to cover Pre-Spinoff Alair Claim Loss (the “Alair
Allocation Amount”) shall, in the aggregate, not exceed the greater of (A) fifty percent (50%) of the Coverage Limit of such Broncus Insurance Policy or (B) an amount equal to the Coverage Limit of such Broncus Insurance
Policy minus the total amount of Other Claim Loss that is entitled to be paid or covered by such Broncus Insurance Policy; and (ii) the maximum dollar amount of the coverage of such Broncus Insurance Policy that is allocable to cover Other
Claim Loss (the “Other Allocation Amount”) shall, in the aggregate, not exceed the greater of (A) fifty percent (50% ) of the Coverage Limit of such Broncus Insurance Policy or (B) an amount equal to the Coverage
Limit of such Broncus Insurance Policy minus the total amount of Pre-Spinoff Alair Claim Loss that is entitled to be paid or covered by such Broncus Insurance Policy. 
  

 5 

 (b) Reimbursement. If for any reason the payments made under a Broncus
Insurance Policy in respect of Pre-Spinoff Alair Claim Loss exceed the Alair Allocation Amount for such policy and the remaining coverage under such policy is insufficient to cover in full all Other Claim Loss that would otherwise be covered by such
Broncus Insurance Policy, then Asthmatx shall reimburse Broncus for that amount of Other Claim Loss for which coverage would otherwise have been (but is not) available under such Broncus Insurance Policy; provided however, that the
amount of such reimbursement by Asthmatx shall not exceed the aggregate amounts paid under such Broncus Insurance Policy in respect of all Pre-Spinoff Alair Claim Loss minus the Alair Allocation Amount for such Broncus Insurance Policy. Likewise, if
for any reason payments made under a Broncus Insurance Policy in respect of Other Claim Loss exceed the Other Allocation Amount for such policy and the remaining coverage under such policy is insufficient to cover in full all Pre-Spinoff Alair Claim
Loss that would otherwise be covered by such Broncus Insurance Policy, then Broncus shall reimburse Asthmatx for that amount of Pre-Spinoff Alair Claim Loss for which coverage would otherwise have been (but is not) available under such Broncus
Insurance Policy; provided however, that the amount of such reimbursement by Broncus shall not exceed the aggregate amounts paid under such Broncus Insurance Policy in respect of all Other Claim Loss minus the Other Allocation Amount
for such Broncus Insurance Policy. Broncus and Asthmatx shall each bear their own cost, and shall not be reimbursed by the other party for, any Pre-Spinoff Alair Claim Loss such party suffers or incurs that is subject to an insurance deductible
under a Broncus Insurance Policy. As used herein, the “Coverage Limit” of a Broncus Insurance Policy means the total dollar amount of insurance coverage available under such policy as of the Effective Date of this Agreement.

 (c) Other Terms. Nothing in this Section 5.3 limits either party’s indemnification obligations set
forth in Sections 2 and 3 above for any Loss incurred after taking into account insurance payments, but rather is intended to set forth how the parties desire to allocate insurance proceeds. The agreements set forth in this Section 5.3 are
intended solely to address the respective rights of the parties and are not intended to modify the terms of any Broncus Insurance Policy. 
 (d) Examples. Exhibit “A” to this Agreement contains examples that illustrate the operation of this Section 5.3. 
 5.4 Certain Covenants. In the event that either party becomes aware of a claim, demand, suit, action, investigation or
proceeding for which it may be entitled to indemnification under Section 2, 3 or 5.2 of this Agreement, then such party (“Indemnified Party”) shall: 
 (a) provide written notice to the other party (“Indemnifying Party”) of such claim, demand, suit, action,
investigation or proceeding promptly, and in no event later than thirty (30) days, after it has knowledge of such claim, demand, suit, action, investigation or proceeding; 
  

 6 

 (b) permit the Indemnifying Party (but only if the Indemnifying Party so chooses,
in its sole and absolute discretion) to assume full responsibility to investigate, prepare for, defend against, and/or settle, all at the Indemnifying Party’s own expense, any such claim, demand, suit, action, investigation or proceeding; and

 (c) assist and cooperate with the Indemnifying Party in the investigation of, preparation for, defense of, and/or
settlement of any such claim, demand, suit, action, investigation or proceeding. 
 In no case shall the Indemnified Party or any of its
employees, officers, directors, consultants or agents compromise, settle, and/or admit to, any such claim, demand, suit, action, investigation or proceeding without the Indemnifying Party’s prior written consent, which shall not be unreasonably
withheld or delayed. 
 6. No Third Party Rights. Except for any third party who is a permitted assignee of this Agreement in
accordance with the terms of Section 7.7 hereof, no third party shall be a beneficiary of this Agreement or any of its provisions, nor shall any third party have any right or ability to enforce this Agreement or any of its provisions, or to
assert any rights under, pursuant to or in connection with this Agreement. 
 7. General Provisions. 
 7.1 Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of California,
without giving effect to that body of laws pertaining to conflict of laws. 
 7.2 Further Assurances. The
parties agree to execute such further documents and instruments and to take such further actions as may be reasonably necessary to carry out the purposes and intent of this Agreement. 
 7.3 Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which when so
executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Agreement may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have
the same effect as if the original signature had been delivered to the other party. 
 7.4 Severability. If any
provision of this Agreement is determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties
hereto. If such clause or provision cannot be so enforced, then such provision shall be stricken from this Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the
extent not enforceable) never been contained in this Agreement. 
 7.5 Notices. Any and all notices required or
permitted to be given to a party pursuant to the provisions of this Agreement will be in writing and will be effective 

  

 7 

 
and deemed to provide such party sufficient notice under this Agreement on the earliest of the following: (i) at the time of personal delivery, if
delivery is in person; (ii) one (1) business day after deposit with an express overnight courier for United States deliveries, or two (2) business days after such deposit for deliveries outside of the United States, with proof of
delivery from the courier requested; or (iii) three (3) business days after deposit in the United States mail by certified mail (return receipt requested) for United States deliveries. All notices for delivery outside the United States
will be sent by express courier. All notices not delivered personally will be sent with postage and/or other delivery charges prepaid and properly addressed to the party to be notified at the address set forth on the signature page to this Agreement
(or at such other address as the party to be notified may have designated to the other party by one of the indicated means of notice herein). 
 7.6 Amendment and Waivers. This Agreement may not be altered or amended except by an instrument in writing executed by Broncus and Asthmatx. No rights of a party under this Agreement may be waived,
except by an instrument in writing executed by such party. No waiver of any terms, provision or condition of or failure to exercise or delay in exercising any rights or remedies under this Agreement, in any one or more instances shall be deemed to
be, or construed as, a further or continuing waiver of any such term, provision, condition, right or remedy or as a waiver of any other term, provision or condition of this Agreement. 
 7.7 Successors and Assigns. No party to this Agreement (“Assigning Party”) may assign this Agreement
or delegate its rights hereunder except: (a) with the written consent of the other party hereto; (b) by operation of law pursuant to a statutory merger or consolidation in which such Assigning Party is merged or consolidated with one or
more other corporations or other entities; or (c) in connection with a sale of all or substantially all such Assigning Party’s assets and properties to a third party who expressly agrees in writing with the other party to this Agreement to
assume and be obligated and liable for, all of the Assigning Party’s obligations under this Agreement. 
 [The remainder of this page
has intentionally been left blank] 
  

 8 

 7.8 Entire Agreement. This Agreement and the documents referred to herein
and exhibits hereto constitute the entire agreement and understanding of the parties with respect to the subject matter of this Agreement, and supersede all prior understandings and agreements, whether oral or written, between or among the parties
hereto with respect to the specific subject matter hereof. 
 IN WITNESS WHEREOF, the
parties hereto have executed this INDEMNIFICATION AGREEMENT as of the Effective Date set forth in the first paragraph of this Agreement. 
  

									
	ASTHMATX, INC.	 		 	BRONCUS TECHNOLOGIES, INC.
					
	By:	 	/s/ Glen French	 		 	By:	 	/s/ Cary Cole
		 	Glen French, President	 		 		 	Cary Cole, President
			
	Address:	 		 	Address:
	1340 Space Park Way	 		 	1400 North Shoreline Blvd, Suite A8
	Mountain View, CA 94043	 		 	Mountain View, CA 94043

 Attachments: 
  

			
		
	 Exhibit “A”:
	 	Certain Examples of the Operation of Section 5.3

  

 9 

 Exhibit “A” 
 Certain Examples of the Operation of Section 5.3 
 The following hypothetical examples
are intended to illustrate the operation of Section 5.3 of this Indemnification Agreement. 
 Example 1: Assume that a Broncus Insurance
Policy has a $10.0 million Coverage Limit and that (i) a $10.0 million payment is made under such policy in respect of Pre-Spinoff Alair Claim Loss, and (ii) subsequently, $6.0 million of Other Claim Loss is incurred by Broncus that would
otherwise have been (but is not) covered by such Broncus Insurance Policy. In this example, Asthmatx would be obligated to reimburse Broncus for $5.0 million of the $10.0 million that was paid from such Broncus Insurance Policy in respect of
Pre-Spinoff Alair Claim Loss and the remaining $1.0 million of such Other Claim Loss would be the responsibility of Broncus (either because it was direct liability of Broncus or because Broncus is obligated to indemnify Broncus for such $1.0 million
of Other Claim Loss under Section 3 of this Agreement). 
 Section 5.3 limits the amount of Asthmatx’s reimbursement for uncovered Other
Claim Loss to the aggregate amounts paid under such Broncus Insurance Policy in respect of all Pre-Spinoff Alair Claim Loss (in this example $10.0 million) minus the Alair Allocation Amount for such Broncus Insurance Policy (in this example
$5.0 million). In this example, the Alair Allocation Amount is $5.0 million because that is the greater of (i) 50% of the $10.0 million Coverage Limit of the Broncus Insurance Policy or (ii) the $10.0 million Coverage Limit of such Broncus
Insurance Policy minus the $6.0 million of Other Claim Loss entitled to be paid or covered by such Broncus Insurance Policy. 
 Example 2:
Assume that a Broncus Insurance Policy has a $10.0 million Coverage Limit and that (i) a $7.0 million payment is made under such policy in respect of Other Claim Loss, (ii) a $2.0 million payment is also made under such policy in respect
of Pre-Spinoff Alair Claim Loss, and (iii) subsequently, an additional $6.0 million of Pre-Spinoff Alair Claim Loss is incurred (such $6.0 million of Pre-Spinoff Alair Claim Loss is referred to in this example as the “Remaining Alair
Claim Loss”). In this example, Broncus would be obligated to reimburse Asthmatx for $2.0 million of the $7.0 million that was paid from such Broncus Insurance Policy in respect of Other Claim Loss. Such $2.0 million payment would
reduce the Remaining Alair Claim Loss to $4.0 million, of which (i) $1.0 million could be covered by the Broncus Insurance Policy and (ii) $3.0 million would be the responsibility of Asthmatx (either because it was direct liability of
Asthmatx or because Asthmatx is obligated to indemnify Broncus for such $3.0 million of Loss under Section 2 of this Agreement). 
 Section 5.3
limits the amount of Broncus’ reimbursement for uncovered Pre-Spinoff Alair Claim Loss to the aggregate amounts paid under such Broncus Insurance Policy in respect of all Other Claim Loss (in this example $7.0 million) minus the Other
Allocation 

  

 10 

 
Amount for such Broncus Insurance Policy (in this example $5.0 million). In this example, the Other Allocation Amount is $5.0 million because that is the
greater of (i) 50% of the $10.0 million Coverage Limit of the Broncus Insurance Policy or (ii) the $10.0 million Coverage Limit of such Broncus Insurance Policy minus the $8.0 million of Pre-Spinoff Alair Claim Loss entitled to be paid or
covered by such Broncus Insurance Policy. 
 Example 3: Assume that a Broncus Insurance Policy has a $10.0 million
Coverage Limit and that (i) a $9.0 million payment is made under such policy in respect of Pre-Spinoff Alair Claim Loss, and (ii) no other claims for coverage are made against such Broncus Insurance Policy. In this example, neither
Broncus nor Asthmatx would have any obligation to reimburse the other for any amounts under Section 5.3. 
  

 11Agreement Not to Sue, dated as of April 30, 1997

 Exhibit 10.25 
 AGREEMENT NOT TO SUE 
 THIS AGREEMENT NOT TO SUE (the “Agreement”) is made and
entered into effective as of the 30th day of April, 1997, by and among VNUS MEDICAL TECHNOLOGIES, INC., a Delaware corporation having its principal place of business at Sunnyvale, California (“Vnus”), SURx, INC., a Delaware
corporation having is principal place of business at Pleasanton, California (“SURx”), CORDIAL MEDICAL, INC., a Delaware corporation having its principal place of business at Tustin, California (“Cordial”), and BRONCUS
TECHNOLOGIES, INC., a California corporation, having its principal place of business at Mountain View, California (“Broncus”). Vnus, SURx, Cordial and Broncus may be herein referred to individually as a “Party” and
collectively as “Parties”. 
 RECITALS 
 WHEREAS, Vnus, Menlo Ventures VI, L.P. and Michael D. Laufer, M.D. (“Dr. Laufer”) entered into an agreement dated April 30, 1997, a copy of which is appended hereto as Exhibit A (the
“Vnus Agreement”), pursuant to which Dr. Laufer and Menlo Ventures VI, L.P. assigned to Vnus his, its and their right, title and interest in certain inventions, improvements, trade secrets, patents, patent applications and in process
patent applications (collectively, “Inventions”) related to the field of chronic venous insufficiency, hemorrhoid treatments, endovascular treatments for vasogenic impotence and the treatment of esophageal varices (the “Vnus
Field”) and agreed to assign to Vnus any future Inventions or intellectual property in the Vnus Field arising out of Dr. Laufer’s work done on behalf of Vnus; and 
 WHEREAS, SURx, Menlo Ventures VI, L.P. and Dr. Laufer entered into an agreement dated April 30,1997, a copy of which is appended hereto
as Exhibit B (the SURx Agreement”), whereby Dr. Laufer and Menlo Ventures VI, L.P. assigned to SURx his, its and their right, title and interest in certain Inventions related to the field of the treatment of urinary incontinence,
fascia in and remaining in the torso (excluding the pericardium), and kidney stones (the “SURx Field”) and agreed to assign to SURx any future Inventions or intellectual property in the SURx Field arising out of Dr. Laufer’s work
done on behalf of SURx; and 
 WHEREAS, Cordial, Menlo Ventures VI, L.P. and Dr. Laufer entered into an agreement dated
April 30,1997, a copy of which is appended hereto as Exhibit C (the “Cordial Agreement”), whereby Dr. Laufer and Menlo Ventures VI, L.P. assigned to Cordial his, its and their right, title and interest in certain Inventions
related to the field of treatment of the heart and pulmonary vessels (the “Cordial Field”) and agreed to assign to Cordial any future Inventions or intellectual property in the Cordial Field arising out of Dr, Laufer’s work done on
behalf of Cordial; and 
 WHEREAS, Broncus, Menlo Ventures VII, L.P., and Dr. Laufer entered into an agreement dated
April 30, 1997, a copy of which is appended as Exhibit D (the “Broncus Agreement”), whereby Dr. Laufer and Menlo Ventures VII, L.P. assigned to Broncus his, its and their right, title and interest in certain Inventions
related to the field of pulmonary assist devices and treatment of the airways of the lungs (the “Broncus Field”), and agreed to assign to Broncus any future Inventions or intellectual property in the Broncus Field arising out of
Dr. Laufer’s work done on behalf of Broncus; and 
 WHEREAS, the Parties desire to have freedom to operate in the respective
fields of the Parties and to avoid any disputes or conflicts based upon or relating to the past and future assignments made by Dr. Laufer under the Vnus Agreement, SURx Agreement, Cordial Agreement, and Broncus Agreement (the “Assignment
Agreements”); and 
 WHEREAS, the Parties wish to provide each other mutual covenants that a Party will not sue another Party in
the event that such other Party, acting in its field, infringes such Party’s rights in Inventions acquired pursuant to the applicable Assignment Agreement; and 
 WHEREAS, the parties desire to avoid potential difficulties in enforcement of legal rights against third parties by a Party enforcing its rights in Inventions owned by such Party pursuant to one of the
Assignment Agreements; 

 NOW THEREFORE, in consideration of the mutual covenants herein contained and intending to be
legally bound thereby, the Parties hereto agree as follows: 
 ARTICLE 1 
 1.1 Vnus hereby covenants that Vnus will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or proceeding (an
“Action”) against SURx, SURx’s agents, representatives, customers, distributors, subdistributors or customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees, affiliates,
subsidiaries, stockholders, predecessors, successors, or assigns (or any person acting by, through, under or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense
or counterclaim, or by any other means in any court within any jurisdiction where such Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of SURx within the SURx Field, or
practice of a process by or on behalf of SURx within the SURx Field infringes or violates any of Vnus’ rights in the Inventions that have been at that time assigned to and are owned by Vnus pursuant to the Vnus Agreement. This covenant does not
in any way impair the right of Vnus to sue any Potentially Infringing Party on account of such Potentially Infringing Party’s activities outside of the SURx Field. 
 1.2 SURx hereby covenants that SURx will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or proceeding (an “Action”) against Vnus, Vnus’ agents,
representatives, customers, distributors, subdistributors or customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees, affiliates, subsidiaries, stockholders, predecessors, successors, or
assigns (or any person acting by, through, under or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense or counterclaim, or by any other means in any court
within any jurisdiction where such Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of Vnus within the Vnus Field, or practice of a process by or on behalf of Vnus within
the Vnus Field infringes or violates any of SURx’s rights in the Inventions that have been at that time assigned to and are owned by SURx pursuant to the SURx Agreement. This covenant does not in any way impair the right of SURx to sue any
Potentially Infringing Party on account of such Potentially Infringing Party’s activities outside of the Vnus Field. 
 ARTICLE 2 

 2.1 Vnus hereby covenants that Vnus will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or
proceeding (an “Action”) against Broncus, Broncus’ agents, representatives, customers, distributors, subdistributors or customers of such. distributors, or subdistributors, partners, directors, officers, attorneys, employees,
affiliates, subsidiaries, stock (or any person acting by, through, under or in concert with any of them) (collectively’ “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense or counterclaim, or by any
other means in any court within any jurisdiction where such Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service fay or on behalf of Broncus within the Broncus Field, or practice of a
process by or on behalf of Bioncus within the Broncus Field infringes or violates any of Vnus’ rights in the lnventions that have been at that-time assigned to and are owned by Vnus pursuant to the Vnus Agreement. This covenant does not in any
way impair the right of Vnus to sue any Potentially Infringing Party on account of such Potentially Infringing Party’s activities outside of the Broncus Field. 
 2.2 Broncus hereby covenants that Broncus will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or proceeding (an “Action”) against Vnus, Vnus’ agents,
representatives, customers, distributors, subdistributors or customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees, affiliates, subsidiaries, stockholders, predecessors, successors, or
assigns (or any person acting by, through, under or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense or counterclaim, or by any other means in any court
within .any jurisdiction where such Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of Vnus within the Vnus Field, or practice of a process by or on behalf of Vnus
within the Vnus Field infringes or violates any of Broncus’ rights in the Inventions that have been at that time assigned to and are owned by Broncus pursuant to the Broncus Agreement. This covenant does not in any way impair the right of
Broncus to sue any Potentially Infringing Party on account of such Potentially Infringing Party’s activities outside of the Vnus Field. 

 ARTICLE 3 
 3.1 Vnus hereby covenants that Vnus will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or proceeding (an “Action”) against Cordial, Cordial’s agents,
representatives, customers, distributors, subdistributors or customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees, affiliates, subsidiaries, stockholders, predecessors, successors, or
assigns (or any person acting by, through, under or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense or counterclaim, or by any other means in any court
within any jurisdiction where such Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of Cordial within the Cordial Field, or practice of a process by or on behalf of
Cordial within the Cordial Field infringes or violates any of Vnus’ rights in the Inventions that have been at that time assigned to and are owned by Vnus pursuant to the Vnus Agreement. This covenant does not in any way impair the right of
Vnus to sue any Potentially Infringing Party on account of such Potentially Infringing Party’s activities outside of the Cordial Field. 
 3.2 Cordial hereby covenants that Cordial will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or proceeding (an “Action”) against Vnus, Vnus’ agents, representatives, customers,
distributors, subdistributors or customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees, affiliates, subsidiaries, stockholders, predecessors, successors, or assigns (or any person acting by,
through, under or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense or counterclaim, or by any other means in any court within any jurisdiction where such
Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of Vnus within the Vnus Field, or practice of a process by or on behalf of Vnus within the Vnus Field infringes or
violates any of Cordial’s rights in the Inventions that have been at that time assigned to and are owned by Cordial pursuant to the Cordial Agreement This covenant does not in any way impair the right of Cordial to sue any Potentially
Infringing Party on account of such Potentially Infringing Party’s activities outside of the Vnus Field. 
 ARTICLE 4 

4.1 Broncus hereby covenants that Broncus will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or
proceeding (an “Action”) against SURx, SURx’s agents, representatives, customers, distributors, subdistributors or ‘ customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees,
affiliates, subsidiaries, stockholders, predecessors, successors, or assigns (or any person acting by, through, under or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by
cross-complaint, defense or counterclaim, or by any other means in any court within any jurisdiction where such Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of SURx
within the SURx Field, or practice of a process by or on behalf of SURx. within the SURx Field infringes or violates any of Broncus’ rights in the Inventions that have been at that time assigned to and are owned by Broncus pursuant to
the Broncus Agreement. This covenant does not in any way impair the right of Broncus to sue any Potentially Infringing Party on account of such Potentially Infringing Party’s activities outside of the SURx Field. 
 4.2 SURx hereby covenants that SURx will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or proceeding (an
“Action”) against Broncus, Broncus’ agents, representatives, customers, distributors, subdistributors or customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees, affiliates,
subsidiaries, stockholders, predecessors, successors, or assigns (or any person acting by, through, under or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense
or counterclaim, or by any other means in any court within any jurisdiction where such Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of Broncus within the Broncus
Field, or practice of a process by or on behalf of Broncus within the Broncus Field infringes or violates any of SURx’s rights in the Inventions that have been at that time assigned to and are owned by SURx pursuant to the SURx Agreement. This
covenant does not in any way impair the right of SURx to sue any Potentially Infringing Party on account of such Potentially Infringing Party’s activities outside of the Broncus Field. 

 ARTICLE 5 
 5.1 Cordial hereby covenants that Cordial will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or proceeding (an “Action”) against SURx, SURx’s agents,
representatives, customers, distributors, subdistributors or customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees, affiliates, subsidiaries, stockholders, predecessors, successors, or
assigns (or any person acting by, through, under or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense or counterclaim, or by any other means in any court
within any jurisdiction where such Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of SURx within the SURx Field, or practice of a process by or on behalf of SURx within
the SURx Field infringes or violates any of Cordial’s rights in the Inventions that have been at that time assigned to and are owned by Cordial pursuant to the Cordial Agreement This covenant does not in any way impair the right of Cordial to
sue any Potentially Infringing Party, on account of such Potentially Infringing Party’s activities outside of the SURx Field. 
 5.2
SURx hereby covenants that SURx will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or proceeding (an “Action”) against Cordial, Cordial’s agents, representatives, customers, distributors,
subdistributors or customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees, affiliates, subsidiaries, stockholders, predecessors, successors, or assigns (or any person acting by, through, under
or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense or counterclaim, or by any other means in any court within any jurisdiction where such Action alleges or
claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of Cordial within the Cordial Field, or practice of a process by or on behalf of Cordial within the Cordial Field infringes or violates any
of SURx’s rights in the Inventions that have been at that time assigned to and are owned by SURx pursuant to the SURx Agreement. This covenant does not in any way impair the right of SURx to sue any Potentially Infringing Party on account of
such Potentially Infringing Party’s activities outside of the Cordial Field. 
 ARTICLE 6 
 6.1 Cordial hereby covenants that Cordial will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or proceeding
(an “Action”) against Broncus, Broncus’ agents, representatives, customers, distributors, subdistributors or customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees, affiliates,
subsidiaries, stockholders, predecessors, successors, or assigns (or any person acting by, through, under or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense
or counterclaim,’ or by any other means in any court within any jurisdiction where such Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of Broncus within the
Broncus Field, or practice of a process by or on behalf of Broncus within the Broncus Field infringes or violates any of Cordial’s rights in the Inventions that have been at that time assigned to and are owned by Cordial pursuant to the Cordial
Agreement. This covenant does not in any way impair the right of Cordial to sue any Potentially Infringing Party on account of such Potentially Infringing Party’s activities outside of the Broncus Field. 
 6.2 Broncus hereby covenants that Broncus will not institute, maintain, prosecute or voluntarily aid any legal or equitable action or proceeding
(an “Action”) against Cordial, Cordial’s agents, representatives, customers, distributors, subdistributors or customers of such distributors or subdistributors, clients, partners, directors, officers, attorneys, employees, affiliates,
subsidiaries, stockholders, predecessors, successors, or assigns (or any person acting by, through, under or in concert with any of them) (collectively, “Potentially Infringing Parties”), whether affirmatively, by cross-complaint, defense
or counterclaim, or by any other means in any court within any jurisdiction where such Action alleges or claims that the manufacture, use, importation, offer to sell, or sale of a product or service by or on behalf of Cordial within the Cordial
Field, or practice of a process by or on behalf of Cordial within the Cordial Field infringes or violates any of Broncus’ rights in the Inventions that have been at that time assigned to and are owned by Broncus pursuant to the Broncus
Agreement. This covenant does not in any way impair the right of Broncus to sue any Potentially Infringing Party on account of such Potentially Infringing Party’s activities outside of the Cordial Field. 

 ARTICLE 7 
 7.1 In the event that a Party institutes a legal or equitable proceeding or action (whether directly or by cross-complaint, counterclaim or as a defense) against a Third Party (i.e., an entity or person not
party to this Agreement), in which the Party alleges that the Third Party has unlawfully infringed or violated such Party’s rights in the Inventions assigned to the Party pursuant to the applicable Assignment Agreement, and should such Third
Party assert that one or more of the other Parties to this Agreement are necessary and indispensable to such legal or equitable proceedings, such other Party or Parties agree to participate in the proceedings. The Party instituting the action shall
be responsible for all liabilities, costs and expenses of the other Party or Parties in participating in such suit The Party instituting the action shall indemnify and hold harmless the other Party or Parties participating in such suit for any
monetary award to the Third Party. The Party instituting the action shall receive all awards and proceeds resulting from settlement, decision or other resolution of such proceeding or action. 
 7.2 No party may require that the Party to whom an invention is assigned institute a proceeding or action against a Third Party alleging that the
Third Party has unlawfully infringed or violated its rights or the rights of the Party to whom an Invention is assigned. 
 ARTICLE 8 

 8.1 The parties agree that Dr. Laufer has full and sole authority to decide the Party to which he assigns Inventions pursuant
to the Assignment Agreements. If a patent application is filed based upon one of his Inventions, Dr. Laufer shall assign his entire rights, title and interest in the application to the same Party to whom he decided to assign the corresponding
Invention. Dr. Laufer’s decisions to assign the patent application to a particular Party shall not be contestable by any of the other Parties. 
 8.2 The Parties recognize as valid, and agree not to contest, the assignments already completed by Dr. Laufer pursuant to the Assignment Agreements. 
 8.3 The Parties recognize as valid, and agree not to contest, any future assignments Dr. Laufer may make pursuant to the Assignment
Agreements. 
 ARTICLE 9 
 9.1 In the event that a Party (the “Initiating Party”) institutes an Action against one of the other Parties (the “Defending Party”) to this Agreement which Action may be determined by a court of competent
jurisdiction or an arbitrator with jurisdiction over such matter to be in breach of a covenant not to sue under Articles 1 through 6 herein, such Initiating Party shall pay all of the Defending Party’s attorney’s fees and costs and
expenses associated with defending against such Actions and enforcing the covenant not to sue. In addition, the Initiating Party shall be liable to the Defending Party for all harm caused by such breach and the Parties agree that equitable relief
may be appropriate including temporary and permanent injunctions. Not withstanding the foregoing, in no event shall any Party be liable under this Article 9.1 to any other Party for any special, punitive, or consequential damages. 

ARTICLE 10 
 10.1
Transferability. A Party’s obligations under this Agreement, including the obligation pursuant to Articles 1-6, not to sue another Party for actions within the other Party’s Field, will bind the Party’s respective successors,
heirs, executors, licensees, administrators, and assigns. A Party cannot license or assign rights in the Inventions assigned to it pursuant to the applicable Assignment Agreement without also assigning the Party’s obligations under this
Agreement. The Parties’ rights pursuant to Articles 7, 8 and 9 of this Agreement will inure to the benefit of their respective successors, heirs, executors, licensees, administrators and assigns. This Agreement authorizes a Party to transfer
the right pursuant to Articles 1-6, not to be sued by another Party only concurrently with the transfer of the entire assets of the Party. The Party transferring its rights and/or obligations under this Agreement must make a written notification of
such transfer to each of the other Parties. The written notification must state to whom the rights and/or obligations are transferred and that the transferee is aware of this Agreement. 
 10.2 Relationship of the Parties. No Party is, nor will be deemed to be, an agent or legal representative of any other Party for any purpose. No
Party will be entitled to enter into any contracts in the name of or on behalf of any other Party, and no Party will be entitled to pledge the credit of any other Party in any way or hold itself out as having authority to do so. No Party will incur
any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein. 

 10.3 Waiver. Unless the provision provides otherwise, no provision of the Agreement will be waived
by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. 
 10.4 Severability. Whenever possible, each provision of the Agreement will be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of the Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of the
Agreement. 
 10.5 Choice of Law. This Agreement shall be governed by and construed in accordance with the laws of the state of
California, as applied to agreements executed and performed entirely within the state of California by California residents. Any claim or controversy arising out of or related to this Agreement or any breach hereof shall be submitted to a court of
applicable jurisdiction in the state of California, and each Party hereby consents to the jurisdiction and venue of such court. 
 10.6
Termination. This Agreement shall continue in effect until the later of March 1,2002 or the expiration of the last to expire of any patents that issue from the Inventions assigned to the Parties pursuant to the Assignment Agreements.

 10.7 Entire Agreement of the Parties. This Agreement sets forth the entire understanding and agreement between the Parties
regarding the subject matter hereof. No verbal agreement, conversation or representation between any officers, agents or employees of the Parties either before or after the execution of this Agreement shall affect or modify any of the terms or
obligations herein contained. 
 10.8 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be
an original and all of which shall constitute together the same document. 
 10.9 No amendment or modification to this Agreement shall
be effective unless in writing signed by each of the Parties hereto. 
 IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement, including Exhibits A, B, C and D attached hereto and incorporated herein by reference. 
  

									
	VNUS MEDICAL TECHNOLOGIES, INC.	 		 	SURx, INC.
					
	By:	 	/s/ Brian E. Farley	 		 	By:	 	/s/ Garry L. Carter
	Title:	 	President & CEO	 		 	Title:	 	President & CEO

  

									
	CORDIAL MEDICAL, INC.	 		 	BRONCUS TECHNOLOGIES, INC.
					
	By:	 	/s/ Tony R. Brown	 		 	By:	 	/s/ Glendon E. French
	Title:	 	President & CEO	 		 	Title:	 	President & CEO

 EXHIBIT A 
 AGREEMENT 
 THIS AGREEMENT (the “Agreement”) is made by and among Vnus Medical Technologies, Inc.
(“Vnus”), Menlo Ventures VI, L.P. (“Menlo”) and Michael D. Laufer, M.D. (“Dr. Laufer”) as of April 30, 1997. 
 1. Assignment of Past Inventions. In exchange for one hundred dollars ($100), receipt of which is hereby acknowledged, Dr. Laufer and Menlo hereby assign to Vnus all of his, its and their existing
right, title and interest in and to any and all inventions, improvements, trade secrets, patents, patent applications and in process patent applications (collectively “inventions”) conceived of and reduced to practice by
Dr. Laufer, solely or jointly, on or before May 2, 1996, and which relate to the areas of chronic venous insufficiency, hemorrhoid treatments, endovascular treatments for vasogenic impotence and the treatment of esophageal varices
(collectively the “Field”). Dr. Laufer retains his rights and interest in being named as an author or the principal author in any and all such inventions within the Field. 
 2. Ownership of Future Inventions. Dr. Laufer and Menlo shall assign for valuable consideration to Vnus all of his, its, and their
existing right, title and interest to any invention or discovery, patentable or otherwise, and any development, improvement, trade secret, or other intellectual property within the Field conceived, developed and/or reduced to practice by
Dr. Laufer, alone or in combination with others at Vnus after May 2, 1996, arising from work done on behalf of Vnus, including but not limited to the review or development of products. Dr. Laufer shall have no obligation to
Vnus with respect to any other inventions or discoveries, patentable or otherwise, or for any other development, improvement, trade secret or other intellectual property except as listed above. 
 3. Further Agreements. 
 (a) All prior agreements between Dr. Laufer and Vnus are hereby terminated. Dr. Laufer acknowledges that he is a director of Vnus and will continue to be subject to his fiduciary duties relating to his role as a member of the
board of directors of Vnus. 
 (b) With respect to all inventions and information assigned by Dr. Laufer to Vnus under this
Agreement, Dr. Laufer will assist Vnus in any reasonable manner upon reasonable request to obtain for Vnus’ benefit patents in any and all countries and Dr. Laufer will execute, upon reasonable request, patent applications,
assignments and declarations to or for Vnus or persons designated by it, and any other lawful documents required to carry out the purposes of this Agreement. Dr. Laufer will further assist Vnus in every way including but not limited to
testifying in any suit or proceeding, to enforce any such patents or patent applications. Vnus agrees that it will reimburse Dr. Laufer for any and all out of pocket expenses associated with such enforcement proceedings. In addition, should
such proceedings ensue after such time as Dr. Laufer is no longer a member of the board of directors, Vnus will reimburse Dr. Laufer for his time at a rate mutually agreed upon but not less than $250/hour which can be unilaterally waived
by Dr. Laufer at the time of such proceedings should he so choose. 
 4. Miscellaneous. 
 (a) This Agreement is entered into by Dr. Laufer in order to comply with the management and limited partnership agreements of Menlo Ventures VI,
L.P. and MV Management VI, L.P. of which Dr. Laufer is a General Partner. 
 (b) This Agreement shall be governed by and construed
in accordance with the laws of the State of California, and the parties hereto submit to the exclusive jurisdiction of the courts in California, both state and federal, with respect to the subject matter of this Agreement 
 (c) This Agreement shall not be modified, amended, rescinded, canceled or waived in whole or in part except by written instruments signed by the
parties hereto. 

 (d) This Agreement expresses modifications to existing agreements between the parties. All previous
agreements between the parties are hereby terminated, including all compensation agreements, consulting agreements and agreements for the assignment of intellectual property. 
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above. 
  

									
		 		 	VNUS MEDICAL TECHNOLOGIES, INC.
				
	/s/ Michael D. Laufer	 		 	By:	 	/s/ Brian E. Farley
	Michael D. Laufer, M.D.	 		 	Title:	 	President & CEO
			
	MENLO VENTURES VI, L.P.	 		 	
	BY:	 	MV MANAGEMENT VI, UP.	 		 		 	
		 	ITS GENERAL PARTNER	 		 		 	
					
	By:	 	/s/ H. D. Montgomery	 		 		 	

 EXHIBIT B 
 AGREEMENT 
 THIS AGREEMENT (the “Agreement”) is made by and among SURx, Inc. (“SURx”), Menlo
Ventures VI, L.P. (“Menlo”) and Michael D. Laufer, M.D. (“Dr. Laufer”) as of April 30, 1997. 
 1. Assignment of Past Inventions. In exchange for one hundred dollars ($100), receipt of which is hereby acknowledged, Dr. Laufer and Menlo hereby assign to SURx all of his, its and their existing right, title and interest
in and to any and all inventions, improvements, trade secrets, patents, patent applications and in process patent applications (collectively “inventions”) conceived of and reduced to practice by Dr. Laufer, solely or jointly, on or
before August 1, 1996, and which relate to the treatment of urinary incontinence, fascia in and remaining in the torso (excluding the pericardium), and kidney stones (collectively the “Field”). Dr. Laufer retains his rights and
interest in being named as an author or the principal author in any and all such inventions within the Field. 
 2. Ownership of
Future Inventions. Dr. Laufer and Menlo shall assign for valuable consideration to SURx all of his, its, and their existing right, title and interest to any invention or discovery, patentable or otherwise, and any development, improvement,
trade secret, or other intellectual property within the Field conceived, developed and/or reduced to practice by Dr. Laufer, alone or in combination with others at SURx after August 1,1996, arising from work done on behalf of SURx,
including but not limited to the review or development of products. Dr. Laufer shall have no obligation to SURx with respect to any other inventions or discoveries, patentable or otherwise, or for any other development, improvement, trade
secret or other intellectual property except as listed above. 
 3. Further Agreements.  
 (a) All prior agreements between Dr. Laufer and SURx are hereby terminated. Dr. Laufer acknowledges that he is a director of SURx and will
continue to be subject to his fiduciary duties relating to his role as a member of the board of directors of SURx. 
 (b) With respect
to all inventions and information assigned by Dr. Laufer to SURx under this Agreement, Dr. Laufer will assist SURx in any reasonable manner upon reasonable request to obtain for SURx’ benefit patents in any and all countries and
Dr. Laufer will execute, upon reasonable request, patent applications, assignments and declarations to or for SURx or persons designated by it, and any other lawful documents required to carry out the purposes of this Agreement Dr. Laufer
will further assist SURx in every way including but not limited to testifying in any suit or proceeding, to enforce any such patents or patent applications. SURx agrees that it will reimburse Dr. Laufer for any and all out of pocket expenses
associated with such enforcement proceedings. In addition, should such proceedings ensue after such time as Dr. Laufer is no longer a member of the board of directors, SURx will reimburse Dr. Laufer for his time at a rate mutually agreed
upon but not less than $250/hour which can be unilaterally waived by Dr. Laufer at the time of such proceedings should he so choose. 
 4. Miscellaneous.  
 (a) This Agreement is entered into by Dr. Laufer in order to comply with the management
and limited partnership agreements of Menlo Ventures VI, L.P. and MV Management VI, L.P. of which Dr. Laufer is a General Partner. 
 (b) This Agreement shall be governed by and construed in accordance with the laws of the State of California, and the parties hereto submit to the exclusive jurisdiction of the courts in California, both state and federal, with respect
to the subject matter of this Agreement. 
 (c) This Agreement shall not be modified, amended, rescinded, canceled or waived in whole or
in part except by written instruments signed by the parties hereto. 

 (d) This Agreement expresses modifications to existing agreements between the parties. All previous
agreements between the parties are hereby terminated, including all compensation agreements, consulting agreements and agreements for the assignment of intellectual property. 
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above. 
  

									
		 		 	SURx INC.
				
	/s/ Michael D. Laufer	 		 	By:	 	/s/ Garry L. Carter
	Michael D. Laufer, M.D.	 		 	Title:	 	President & CEO
				
	MENLO VENTURES VI, L.P.	 		 		 	
	BY:	 	MV MANAGEMENT VI, L.P.	 		 		 	
		 	ITS GENERAL PARTNER	 		 		 	
					
	By:	 	/s/ H. D. Montgomery	 		 		 	

 EXHIBIT C 
 AGREEMENT 
 THIS AGREEMENT (the “Agreement”) is made by and among Cordial Medical, Inc.
(“Cordial”), Menlo Ventures VI, L.P. (“Menlo”) and Michael D. Laufer, M.D. (“Dr. Laufer”) as of April 30, 1997. 
 1. Assignment of Past Inventions. In exchange for one hundred dollars ($ 100), receipt of which is hereby acknowledged, Dr. Laufer and Menlo hereby assign to Cordial all of his, its and their existing
right, title and interest in and to any and all inventions, improvements, trade secrets, patents, patent applications and in process patent applications (collectively “inventions”) conceived of and reduced to practice by Dr. Laufer,
solely or jointly, on or before July 8, 1996, and which relate to treatment of the heart and pulmonary vessels (collectively the “Field”). Dr. Laufer retains his rights and interest in being named as an author or the principal
author in any and all such inventions within the Field. 
 2. Ownership of Future Inventions. Dr. Laufer and Menlo shall
assign for valuable consideration to Cordial all of his, its., and their existing right, title and interest to any invention or discovery, patentable or otherwise, and any development, improvement, trade secret, or other intellectual property within
the Field conceived, developed and/or reduced to practice by Dr. Laufer, alone or in combination with others at Cordial after July 8, 1996, arising from work done on behalf of Cordial, including but not limited to the review or development
of products. Dr. Laufer shall have no obligation to Cordial with respect to any other inventions or discoveries, patentable or otherwise, or for any other development, improvement, trade secret or other intellectual property except as listed
above. 
 3. Further Agreements. 
 (a) All prior agreements between Dr. Laufer and Cordial are hereby terminated. Dr. Laufer acknowledges that he is a director of Cordial and will continue to be subject to his fiduciary duties relating
to his role as a member of the board of directors of Cordial. 
 (b) With respect to all inventions and information assigned by
Dr. Laufer to Cordial under this Agreement, Dr. Laufer will assist Cordial in any reasonable manner upon reasonable request to obtain for Cordial’ benefit patents in any and all countries and Dr. Laufer will execute, upon
reasonable request, patent applications, assignments and declarations to or for Cordial or persons designated by it, and any other lawful documents required to carry out the purposes of this Agreement. Dr. Laufer will further assist Cordial in
every way including but not limited to testifying in any suit or proceeding, to enforce any such patents or patent applications. Cordial agrees that it will reimburse Dr. Laufer for any and all out of pocket expenses associated with such
enforcement proceedings. In addition, should such proceedings ensue after such time as Dr. Laufer is no longer a member of the board of directors, Cordial will reimburse Dr. Laufer for his time at a rate mutually agreed upon but not less
than $250/hour which can be unilaterally waived by Dr. Laufer at the time of such proceedings should he so choose. 
 4. Miscellaneous. 
 (a) This Agreement is entered into by Dr. Laufer in order to comply with the management
and limited partnership agreements of Menlo Ventures VI, L.P. and MV Management VI, L.P. of which Dr. Laufer is a General Partner. 
 (b) This Agreement shall be governed by and construed in accordance with the laws of the State of California, and the parties hereto submit to the exclusive jurisdiction of the courts in California, both state and federal, with respect
to the subject matter of this Agreement. 
 (c) This Agreement shall not be modified, amended, rescinded, canceled or waived in whole or
in part except by written instruments signed by the parties hereto. 

 (d) This Agreement expresses modifications to existing agreements between the parties. All previous
agreements between the parties are hereby terminated, including all compensation agreements, consulting agreements and agreements for the assignment of intellectual property. 
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above. 
  

									
		 		 	CORDIAL MEDICAL, INC.
				
	/s/ Michael D. Laufer	 		 	By:	 	/s/ Tony R. Brown
	Michael D. Laufer, M.D.	 		 	Title:	 	President & CEO
				
	MENLO VENTURES VI, L.P.	 		 		 	
	BY:	 	MV MANAGEMENT VI, L.P.	 		 		 	
		 	ITS GENERAL PARTNER	 		 		 	
					
	By:	 	/s/ H. D. Montgomery	 		 		 	

 EXHIBIT D 
 AGREEMENT 
 THIS AGREEMENT (the “Agreement”) is made by and among Broncus Technologies, Inc.
(“Broncus”), Menlo Ventures VII, L.P. (“Menlo”) and Michael D. Laufer, M.D. (“Dr. Laufer”) as of April 30, 1997. 
 1. Assignment of Past Inventions. In exchange for one hundred dollars ($100), receipt of which is hereby acknowledged, Dr. Laufer and Menlo hereby assign to Broncus all of his, its and their existing
right, title and interest in and to any and all inventions, improvements, trade secrets, patents, patent applications and in process patent applications (collectively “inventions”) conceived of and reduced to practice by Dr. Laufer,
solely or jointly, on or before February 7, 1997, and which relate to the areas of pulmonary assist devices and the treatment of the airways of the lungs (collectively the “Field”). Dr. Laufer retains his rights and interest in
being named as an author or the principal author in any and all such inventions within the Field. 
 2. Ownership of Future
Inventions. Dr. Laufer and Menlo shall assign for valuable consideration to Broncus all of his, its , and their existing right, title and interest to any invention or discovery, patentable or otherwise, and any development, improvement,
trade secret, or other intellectual property within the Field conceived, developed and/or reduced to practice by Dr. Laufer, alone or in combination with others at Broncus after February 7, 1997, arising from work done on behalf of
Broncus, including but not limited to the review or development of products. Dr. Laufer shall have no obligation to Broncus with respect to any other inventions or discoveries, patentable or otherwise, or for any other development, improvement,
trade secret or other intellectual property except as listed above. 
 3. Further Agreements. 
 (a) All prior agreements between Dr. Laufer and Broncus are hereby terminated. Dr. Laufer acknowledges that he is a director of Broncus and
will continue to be subject to his fiduciary duties relating to his role as a member of the board of directors of Broncus. 
 (b) With
respect to all inventions and information assigned by Dr. Laufer to Broncus under this Agreement, Dr. Laufer will assist Broncus in any reasonable manner upon reasonable request to obtain for Broncus’ benefit patents in any and all
countries and Dr. Laufer will execute, upon reasonable request, patent applications, assignments and declarations to or for Broncus or persons designated by it, and any other lawful documents required to carry out the purposes of this
Agreement. Dr. Laufer will further assist Broncus in every way including but not limited to testifying in any suit or proceeding, to enforce any such patents or patent applications. Broncus agrees that it will reimburse Dr. Laufer for any
and all out of pocket expenses associated with such enforcement proceedings. In addition, should such proceedings ensue after such time as Dr. Laufer is no longer a member of the board of directors, Broncus will reimburse Dr. Laufer for
his time at a rate mutually agreed upon but not less than $250/hour which can be unilaterally waived by Dr. Laufer at the time of such proceedings should he so choose. 

 4. Miscellaneous. 
 (a) This Agreement is entered into by Dr. Laufer in order to comply with the management and limited partnership agreements of Menlo Ventures
VII, L.P. and MV Management VII, L.P. of which Dr. Laufer is a General Partner. 
 (b) This Agreement shall be governed by and
construed in accordance with the laws of the State of California, and the parties hereto submit to the exclusive jurisdiction of the courts in California, both state and federal, with respect to the subject matter of this Agreement. 
 (c) This Agreement shall not be modified, amended, rescinded, canceled or waived in whole or in part except by written instruments signed by the
parties hereto. 
 (d) This Agreement expresses modifications to existing agreements between the parties. All previous agreements
between the parties are hereby terminated, including all compensation agreements, consulting agreements and agreements for the assignment of intellectual property. 
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above. 
  

									
		 		 	BRONCUS TECHNOLOGIES, INC.
				
	/s/ Michael D. Laufer	 		 	By:	 	/s/ Glendon E. French
	Michael D. Laufer, M.D.	 		 	Title:	 	President & CEO
				
	MENLO VENTURES VII, L.P.	 		 		 	
	BY:	 	MV MANAGEMENT VI, L.P.	 		 		 	
		 	ITS GENERAL PARTNER	 		 		 	
					
	By:	 	/s/ H. D. Montgomery

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]